Timeline of Events
More than two million scans from thousands of healthcare professionals in 50+ countries around the world have been analyzed. And that’s just the beginning of how we are continuing to redefine stroke care.
For 20+ years, most believed we had only a few hours after a stroke to provide treatment—but we were never satisfied with that thinking. We theorized that stroke evolution was highly variable, the conventional short treatment windows could be upended, and far more people with cerebrovascular disorders could be saved. We recognized that technology was the limiting factor even after an early NIH-funded, multicenter trial showed important advancements. We developed RAPID® (Rapid Processing of Perfusion and Diffusion) to address this need. Fast forward to today...
As the leader in brain imaging analysis, we are delivering proven software tools healthcare professionals around the world use to successfully identify and diagnose more cerebrovascular disorders than ever before possible. We take great pride in the role we continue to play in advancing stroke care and helping healthcare professionals save more lives.
Rapid CTA receives CE approval, becoming the first advanced imaging product indicated for localization of a detected large vessel occlusion (LVO).
Mexico, Brazil, Japan, Israel, and Vietnam join the list of 50+ countries that approve the use of Rapid platform.
RapidAI Insights launches—offering a suite of reports and analytics on Rapid scan, treatment, and outcomes data.
AI-powered Rapid ASPECTS becomes the first ever neuroimaging solution to receive FDA clearance in the CADx (Computer-Assisted Diagnostic software) category.
Machine learning and other stroke artificial intelligence (AI) techniques are changing medicine in profound ways. At RapidAI, we are using it to extract greater meaning from medical imaging data and to develop tools that ultimately help physicians improve patient care.
